Regeneron Ventures | Activity | F4

Introducing F4 Champions, a new accelerator for founders at the earliest stage.F4 Champions for early-stage foundersEnrollment closesAugust 2Learn more

Team Portfolio Raise Champions Essays

F4/Regeneron Ventures/Activity

Regeneron Ventures Activity

Every public signal F4 has attached to this firm, with sources and cross-entity links.

Types

Time range

7 investments· AUG 2025 – AUG 2026Show all

Investment

Co-led Infinimmune's $75M Series A for human-derived antibody drug discovery.

Infinimmune

Infinimmune Regeneron Ventures

fiercebiotech.comAUG 2026

AUG 2026

Investment

Participated in Coultreon Biopharma's $125M Series A for its immunology pipeline.

Coultreon Biopharma

Coultreon Biopharma Regeneron Ventures

globenewswire.comAPR 28, 2026

APR 28, 2026

Investment

Co-led Think Bioscience's oversubscribed $55M Series A for its synthetic biology drug discovery platform.

Think Bioscience

Think Bioscience Regeneron Ventures

prnewswire.comJAN 20, 2026

JAN 20, 2026

Investment

Participated in Triana Biomedicines' oversubscribed $120M Series B for its molecular glue degrader pipeline.

TRIANA Biomedicines

TRIANA Biomedicines Regeneron Ventures

businesswire.comDEC 3, 2025

DEC 3, 2025

Investment

Participated in Iambic Therapeutics' oversubscribed $100M+ Series B for AI-discovered therapeutics.

Iambic

Iambic Regeneron Ventures

businesswire.comNOV 10, 2025

NOV 10, 2025

Investment

Participated in Zag Bio's $80M launch financing for thymus-targeted autoimmune therapies.

Zag Bio

Zag Bio Regeneron Ventures

globenewswire.comOCT 28, 2025

OCT 28, 2025

Investment

Participated in Strand Therapeutics' $153M Series B for its programmable mRNA therapeutics pipeline.

Strand Tx

Strand Tx Regeneron Ventures

businesswire.comAUG 7, 2025

AUG 7, 2025

New Fund

Regeneron Ventures launched as an independent venture fund with a $500 million commitment from Regeneron Pharmaceuticals to back biotechnology innovation.

Regeneron Ventures launch — $500M commitment

Regeneron Ventures

globenewswire.comAPR 15, 2024

APR 15, 2024